AASLD 2016

Daclatasvir-based Tx Shows High Viral Clearance in Liver Transplant Patients

By November 14, 2016

Researchers reported "high efficacy and an excellent safety profile" for direct-acting antiviral (DAA) combinations with daclatasvir (DCV) among transplanted patients with hepatitis C virus (HCV) infection.

SOF-based Regimens Offer New Options for Patients with HCV GT4

By November 14, 2016

Sofosbuvir-based regimens "offer new therapeutic options" for patients with GT4 chroninc hepatitis C virus infection.

EBR/GZR+SOF ± RBV is 'Highly Efficacious' for HCV GT3

By November 14, 2016

The EBR/GZR+SOF±RBV regimen is offers "high efficacy" in treating patients with GT3 Hepatitis C Virus (HCV).

HCV Treatment Patterns in Patients With Advanced CKD: 2010 to 2015

By November 14, 2016

Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) "remains a challenging population to treat," with <10% receiving treatment in the early direct-acting antivirals (DAA) era.

'MK3' Fixed-Dose Combination Effective in HCV GT 1, 2, and 3

By November 14, 2016

A fixed-dose combination of pangenotypic direct-acting antivirals was "highly effective" in treatment-naïve patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3

SOF/VEL/VOX Effective as Retreatment for Non-NS5A DAA Failures

By November 14, 2016

Treatment with single tablet sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks "is a highly effective salvage therapy" for patients who did not previously achieve sustained virologic response (SVR) following treatment with non-NS5A inhibitor-containing direct-acting antivirals (DAAs), results from the POLARIS-4 study presented at The Liver Meeting® 2016 have shown.

3-DAA Regimen Studied in HCV With Bridging Fibrosis, Compensated Cirrhosis

By November 14, 2016

3-DAA ± ribavirin achieved high 12-week sustained virologic response rates in Brazilian patients with GT1 hepatitis C virus (HCV) with bridging fibrosis or compensated cirrhosis.

Beta-Blockers: No Changes in Heart Rate With Concomitant Sofosbuvir

By November 14, 2016

No clinically significant changes in heart rate or cardiac adverse events were observed in patients with hepatitis C virus (HCV) infection on beta blockers receiving sofosbuvir (SOF)-based regimens, results of a study presented at The Liver Meeting® have found.

Opioids Associated With Increased Mortality Among Liver Cirrhosis Patients

By November 14, 2016

Among patients with liver cirrhosis, opioids are associated with increased mortality.

Glecaprevir/Pibrentasvir Achieves High SVR12 Rates in Non-cirrhotic HCV GT 4-6

By November 14, 2016

The all-oral, ribavirin-free glecaprevir/pibrentasvir regimen achieved high SVR12 rates in non-cirrhotic patients with hepatitis C virus (HCV) genotype (GT) 4, 5, and 6 infection, the phase 3 ENDURANCE-4 study concluded at The Liver Meeting® 2016.

Oral Rifaximin Might Reduce Hospitalization, Mortality in Liver Cirrhosis

By November 14, 2016

An investigational oral 40mg immediate-release rifaximin formulation reduces hospitalization and mortality in patients with cirrhosis with well-controlled ascites.

IFN-free DAA Regimens Found Safe and Effective for Elderly Patients

By November 14, 2016

IFN-free DAA regimens are safe and effective for elderly patients with hepatitis C virus (HCV)-related cirrhosis or severe fibrosis.

Long-term PPI Use Reduces Bleeding-Related Mortality in Cirrhosis Patients

By November 14, 2016

Long-term use of proton pump inhibitors (PPIs) reduces bleeding-related mortality in patients with cirrhosis and variceal bleeding, a prospective study reported at The Liver Meeting® 2016.

LDV/SOF ± RBV, OPrD Effective in HIV/HCV Co-Infected Veterans

By November 14, 2016

Ledipasvir/Sofosbuvir with or without ribavirin is associated with comparable sustained virologic response (SVR) rates for African American patients and non-African Americans who have HIV/HCV co-infection, but cirrhosis was associated with significantly poorer rates.

Tenofovir Alafenamide Shows No Resistance at Week 48 in Chronic HBV

By November 14, 2016

No resistance to tenofovir alafenamide (TAF) was detected through week 48 in adults with chronic hepatitis B virus (HBV), regardless of whether they were treatment-naïve or -experienced, results of two phase 3 studies presented at The Liver Meeting® 2016 have shown.

Telbivudine, Tenofovir Prevent Mother-to-Infant HBV Transmission

By November 14, 2016

Use of telbivudine and tenofovir in middle-to-late pregnancy was equally effective in reducing mother-to-infant chronic hepatitis B virus (HBV) infection vertical transmission, a real world study in China reported at The Liver Meeting® 2016

IFN-Free Regimen Achieves 100% SVR in HCV Patients With Thalassemia Major

By November 13, 2016

Ledipasvir and sofosbuvir yielded 100% SVR in patients with thalassemia major, a genetic disease, who become infected with hepatitis C virus genotypes 1 and 4.

Adjuvant PegIFN/RBV Ups Survival in HCV/HCC Patients Receiving TACE

By November 13, 2016

In patients with chronic hepatitis C virus (HCV) infection and intermediate stage hepatocellular carcinoma (HCC) who receive transarterial chemoembolization (TACE), the SVR achieved with pegylated-interferon (pegIFN/ribavirin (RBV) treatment markedly improved survival and reduced tumor recurrence, a study presented at The Liver Meeting 2016® concluded.

Does Adding Simvastatin to Carvedilol Help Reduce First Bleed Incidence in Cirrhosis?

By November 13, 2016

Compared with carvedilol alone, adding simvastatin to carvedilol did not improve hemodynamic efficacy or reduce incidence of first bleed in patients with cirrhosis with varices without a prior bleed, preliminary results of an open-label randomized controlled trial reported at The Liver Meeting® 2016

High Efficacy, Improved PROs With SOF/VEL in HCV/HIV Co-Infection

By November 13, 2016

Patient-reported outcome scores improve significantly for HIV-HCV co-infected patients undergoing sofosbuvir and velpatasvir therapy.

Dapagliflozin + Omega-3 Carboxylic Acids Lower Liver Fat in Type 2 Diabetes NAFLD

By November 13, 2016

Combined dapagliflozin (DAPA) and free omega-3 fatty acid carboxylic acids (OM-3 CA) significantly reduce liver fat among patients with type 2 diabetes and non-alcoholic liver disease.

High Real-World Cure Rates With DAA Combo in HCV With Decompensated Cirrhosis

By November 13, 2016

Patients with HCV GT1 with decompensated cirrhosis treated in the real world with ledipasvir/sofosbuvir plus ribavirin achieved high cure rates and comparable MELD improvement to patients in clinical trials.

Drinking Coffee Found to Significantly Decrease NAFLD Risk

By November 13, 2016

Coffee drinkers significantly decrease their risk of nonalcoholic fatty liver disease (NAFLD), and regular drinking also decreases risk of liver fibrosis, according to results of a systematic review and meta-analysis presented at The Liver Meeting® 2016.

Once-Daily Simeprevir, AL-335, and Odalasvir Combination Safe, Effective

By November 13, 2016

A combination of investigative direct-acting antivirals and simeprevir (SMV) is well tolerated in healthy volunteers.

Omega-3 Fatty Acids Reduce Liver Fat in Hepatic Steatosis

By November 13, 2016

Omega-3 fatty acids are associated with a significant reduction in liver fat in patients with hepatic steatosis, a systematic review and meta-analysis presented at The Liver Meeting® 2016 has found.

Remogliflozin Etabonate Reduces FIB-4, NAFLD Scores in T2DM Patients

By November 12, 2016

Remogliflozin Etabonate Reduces FIB-4 and NAFLD Fibrosis Scores in Type 2 Diabetic Subjects

Durable SVR12 Seen With Daclatasvir-Based Regimens for HCV

By November 12, 2016

Long-term follow-up data show that sustained virologic response (SVR) at 12 weeks achieved with daclatasvir (DCV)-based regimens are durable in patients with chronic hepatitic C virus (HCV) infection, study authors reported at The Liver Meeting® 2016.

High SVR Rates With LDV/SOF in 'Real World' HIV/HCV Co-infected Cohorts

By November 12, 2016

Ledipasvir/sofosbuvir therapy for patients with HIV/HCV co-infection is comparably effective in real-world clinical settings and clinical trials.

6-Week SOF/LDV Therapy Found Effective in Acute HCV Genotype 1

By November 12, 2016

At The Liver Meeting® 2016, scientists reported that treatment with ledipasvir/sofosbuvir (LDV/SOF) for 6 weeks was well tolerated and highly effective in patients with acute hepatitis C virus (HCV) GT 1 infection.

Does Concomitant PPI Use Affect Efficacy of Elbasvir/Grazoprevir?

By November 12, 2016

Consistent concomitant use of proton pump inhibitors (PPIs) with elbasvir/grazoprevir (EBR/GZR) had no clinically significant effect on 12-week sustained viral response (SVR12) rates in patients with hepatitis C virus (HCV) genotype (GT)1 or GT4 infection with and without cirrhosis, according to research presented at The Liver Meeting® 2016